Cutaneous Squamous Cell

Adjuvant

Receive study treatment at a min of 4 wks and max of 16 wks after the last dose of RT

ENT0052

SKIn0046
Phase III
Pembrolizumab vs Placebo as in HighRisk Locally Advanced Cutaneous Squamous Cell Carcinoma

PI: Chang
Merck Sharp & Dohme Corp.

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu